¥ 7061
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Very strong margins and returns
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD
Target Price
The average target price of 4519.T is 8433 and suggests 19% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
